| FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression B Li, A Samanta, X Song, KT Iacono, K Bembas, R Tao, S Basu, JL Riley, ... Proceedings of the National Academy of Sciences 104 (11), 4571-4576, 2007 | 483 | 2007 |
| Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma SP D'Angelo, L Melchiori, MS Merchant, D Bernstein, J Glod, R Kaplan, ... Cancer discovery 8 (8), 944-957, 2018 | 375 | 2018 |
| Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation M Beyer, Y Thabet, RU Müller, T Sadlon, S Classen, K Lahl, S Basu, ... Nature immunology 12 (9), 898-907, 2011 | 236 | 2011 |
| Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin S Basu, T Golovina, T Mikheeva, CH June, JL Riley The Journal of Immunology 180 (9), 5794-5798, 2008 | 215 | 2008 |
| Helios induces epigenetic silencing of IL2 gene expression in regulatory T cells I Baine, S Basu, R Ames, RS Sellers, F Macian The Journal of Immunology 190 (3), 1008-1016, 2013 | 141 | 2013 |
| Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma I Ramachandran, DE Lowther, R Dryer-Minnerly, R Wang, S Fayngerts, ... Journal for immunotherapy of cancer 7, 1-14, 2019 | 119 | 2019 |
| Foxp3-mediated inhibition of Akt inhibits Glut1 (glucose transporter 1) expression in human T regulatory cells S Basu, B Hubbard, EM Shevach Journal of Leucocyte Biology 97 (2), 279-283, 2015 | 71 | 2015 |
| γc-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes M Kasprzycka, Q Zhang, A Witkiewicz, M Marzec, M Potoczek, X Liu, ... The Journal of Immunology 181 (4), 2506-2512, 2008 | 66 | 2008 |
| Adoptive immunotherapy: good habits instilled at youth have long-term benefits CM Paulos, MM Suhoski, G Plesa, T Jiang, S Basu, TN Golovina, S Jiang, ... Immunologic research 42, 182-196, 2008 | 52 | 2008 |
| Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells S Oh, X Mao, S Manfredo-Vieira, J Lee, D Patel, EJ Choi, A Alvarado, ... Nature biotechnology 41 (9), 1229-1238, 2023 | 48 | 2023 |
| Regulatory T cells suppress CD4+ T cells through NFAT‐dependent transcriptional mechanisms DS Shin, A Jordan, S Basu, RM Thomas, S Bandyopadhyay, ... EMBO reports 15 (9), 991-999, 2014 | 48 | 2014 |
| Validation of the Cepheid Xpert Flu A real time RT-PCR detection panel for emergency use authorization AR Sambol, PC Iwen, M Pieretti, S Basu, MH Levi, KD Gilonske, ... Journal of Clinical Virology 48 (4), 234-238, 2010 | 34 | 2010 |
| ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma BA Van Tine, MO Butler, D Araujo, ML Johnson, J Clarke, D Liebner, ... Annals of Oncology 30, v684-v685, 2019 | 22 | 2019 |
| 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016 A Lundqvist, V van Hoef, X Zhang, E Wennerberg, J Lorent, K Witt, ... Journal for immunotherapy of cancer 4, 1-106, 2016 | 10 | 2016 |
| Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy D Nunez, D Patel, J Volkov, S Wong, Z Vorndran, F Müller, M Aigner, ... Molecular Therapy-Methods & Clinical Development 31, 2023 | 9 | 2023 |
| A Phase 1 trial of targeted DSG3-CAART cell therapy in mucosal-dominant pemphigus vulgaris (mPV) patients: early cohort data DJ Chang, S Basu, D Porter, M Abedi, WK Weng, R Micheletti, ... MOLECULAR THERAPY 30 (4), 373-373, 2022 | 3 | 2022 |
| LB952 A phase 1 trial of DSG3-CAART cells in mucosal-dominant pemphigus vulgaris (mPV) patients: Preliminary data DJ Chang, S Basu, R Micheletti, E Maverakis, M Marinkovich, DL Porter, ... Journal of Investigative Dermatology 142 (8), B18, 2022 | 1 | 2022 |
| Muscle-specific tyrosine kinase chimeric autoantibody receptor T cells (MuSK-CAART): a precision cellular immunotherapy for antigen-specific B cell depletion in MuSK myasthenia … S Oh, X Mao, S Manfredo-Vieira, EJ Choi, U Herzberg, D Patel, ... MOLECULAR THERAPY 30 (4), 15-15, 2022 | 1 | 2022 |
| Characterization of DSG3-CAART cells prior to & following adoptive transfer in mucosal Pemphigus Vulgaris S Basu, JS Volkov, D Chang, D Nunez, K Hoffman, S Manfredo-Vieira, ... MOLECULAR THERAPY 30 (4), 329-330, 2022 | 1 | 2022 |
| Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma SP D'Angelo, D Araujo, BV Tine, G Demetri, M Dutra, J Glod, W Chow, ... Cancer Immunology Research 7 (2_Supplement), A007-A007, 2019 | 1 | 2019 |
